DeSantis Damon 4
Research Summary
AI-generated summary
Integrated Biopharma (INBP) 10% Owner DeSantis Receives Award
What Happened
- DeSantis Damon (reported as a 10% owner) received a grant of 50,000 derivative securities (reported as an award/acquisition) on 2026-06-24. The Form 4 shows a $0.00 acquisition price, indicating no cash was paid at grant; the filing does not disclose an exercise price or immediate cash value.
Key Details
- Transaction date: 2026-06-24; filing date: 2026-06-25 (filed timely).
- Transaction type/code: A (award/grant) — derivative securities (stock options).
- Amount: 50,000 options granted; price reported = $0.00 (grant price, not exercise price).
- Vesting/exercisability (footnote): 4 equal installments of 12,500 options vest and become exercisable on 9/30/2026, 12/31/2026, 3/31/2027 and 6/30/2027.
- Shares owned after transaction: not specified in the supplied filing excerpt.
- No 10b5-1 plan, tax-withholding, or late-filing flags noted in this filing.
Context
- This is a grant of options (a derivative award), not an open-market purchase — the recipient gains the right to acquire shares later if and when they exercise the options. Such grants are commonly part of compensation or incentive programs and do not by themselves indicate immediate buying or selling pressure. As a reported 10% owner, DeSantis is a significant holder; the grant increases potential future ownership as options vest and are exercised.